187 related articles for article (PubMed ID: 34371177)
1. A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy.
Meeuwsen MH; Wouters AK; Jahn L; Hagedoorn RS; Kester MGD; Remst DFG; Morton LT; van der Steen DM; Kweekel C; de Ru AH; Griffioen M; van Veelen PA; Falkenburg JHF; Heemskerk MHM
Mol Ther; 2022 Feb; 30(2):564-578. PubMed ID: 34371177
[TBL] [Abstract][Full Text] [Related]
2. Selection, engineering, and in vivo testing of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin.
Hiscox MJ; Wasmuth A; Williams CL; Foot JN; Wiedermann GE; Fadda V; Boiani S; Cornforth TV; Wikiert KA; Bruton S; Cartwright N; Anderson VE; Barnes CS; Vieira JV; Birch-Machin I; Gerry AB; Miller K; Pumphrey NJ
PLoS One; 2024; 19(4):e0301175. PubMed ID: 38574067
[TBL] [Abstract][Full Text] [Related]
3. A library of cancer testis specific T cell receptors for T cell receptor gene therapy.
de Rooij MAJ; Remst DFG; van der Steen DM; Wouters AK; Hagedoorn RS; Kester MGD; Meeuwsen MH; Wachsmann TLA; de Ru AH; van Veelen PA; Verdegaal EME; Falkenburg JHF; Heemskerk MHM
Mol Ther Oncolytics; 2023 Mar; 28():1-14. PubMed ID: 36589698
[TBL] [Abstract][Full Text] [Related]
4. An efficient method to identify virus-specific TCRs for TCR-T cell immunotherapy against virus-associated malignancies.
Chen L; Dong L; Ma Y; Wang J; Qiao D; Tian G; Wang M
BMC Immunol; 2021 Sep; 22(1):65. PubMed ID: 34583647
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.
Tsimberidou AM; Guenther K; Andersson BS; Mendrzyk R; Alpert A; Wagner C; Nowak A; Aslan K; Satelli A; Richter F; Kuttruff-Coqui S; Schoor O; Fritsche J; Coughlin Z; Mohamed AS; Sieger K; Norris B; Ort R; Beck J; Vo HH; Hoffgaard F; Ruh M; Backert L; Wistuba II; Fuhrmann D; Ibrahim NK; Morris VK; Kee BK; Halperin DM; Nogueras-Gonzalez GM; Kebriaei P; Shpall EJ; Vining D; Hwu P; Singh H; Reinhardt C; Britten CM; Hilf N; Weinschenk T; Maurer D; Walter S
Cancer Immunol Res; 2023 Jul; 11(7):925-945. PubMed ID: 37172100
[TBL] [Abstract][Full Text] [Related]
6. T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome.
Klebanoff CA; Chandran SS; Baker BM; Quezada SA; Ribas A
Nat Rev Drug Discov; 2023 Dec; 22(12):996-1017. PubMed ID: 37891435
[TBL] [Abstract][Full Text] [Related]
7. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors.
Lu D; Chen Y; Jiang M; Wang J; Li Y; Ma K; Sun W; Zheng X; Qi J; Jin W; Chen Y; Chai Y; Zhang CWH; Liang H; Tan S; Gao GF
Nat Commun; 2023 Oct; 14(1):6389. PubMed ID: 37828002
[TBL] [Abstract][Full Text] [Related]
8. Identification of HPV-E7 specific TCRs for tumor immunotherapy.
Li X; Wang W; Wang J; Jiang M; He J; Tan S
Mol Immunol; 2024 May; 171():56-65. PubMed ID: 38795685
[TBL] [Abstract][Full Text] [Related]
9. Unconventional modes of peptide-HLA-I presentation change the rules of TCR engagement.
Hopkins JR; MacLachlan BJ; Harper S; Sewell AK; Cole DK
Discov Immunol; 2022; 1(1):kyac001. PubMed ID: 38566908
[TBL] [Abstract][Full Text] [Related]
10. Challenges and solutions for therapeutic TCR-based agents.
Malviya M; Aretz ZEH; Molvi Z; Lee J; Pierre S; Wallisch P; Dao T; Scheinberg DA
Immunol Rev; 2023 Nov; 320(1):58-82. PubMed ID: 37455333
[TBL] [Abstract][Full Text] [Related]
11. Membrane fusogenic nanoparticle-based HLA-peptide-addressing universal T cell receptor-engineered T (HAUL TCR-T) cell therapy in solid tumor.
Xu R; Wang Q; Zhu J; Bei Y; Chu Y; Sun Z; Du S; Zhou S; Ding N; Meng F; Liu B
Bioeng Transl Med; 2023 Nov; 8(6):e10585. PubMed ID: 38023696
[TBL] [Abstract][Full Text] [Related]
12. A systematic safety pipeline for selection of T-cell receptors to enter clinical use.
Foldvari Z; Knetter C; Yang W; Gjerdingen TJ; Bollineni RC; Tran TT; Lund-Johansen F; Kolstad A; Drousch K; Klopfleisch R; Leisegang M; Olweus J
NPJ Vaccines; 2023 Aug; 8(1):126. PubMed ID: 37607971
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function.
Salter AI; Rajan A; Kennedy JJ; Ivey RG; Shelby SA; Leung I; Templeton ML; Muhunthan V; Voillet V; Sommermeyer D; Whiteaker JR; Gottardo R; Veatch SL; Paulovich AG; Riddell SR
Sci Signal; 2021 Aug; 14(697):. PubMed ID: 34429382
[TBL] [Abstract][Full Text] [Related]
14. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
Kong W; Dimitri A; Wang W; Jung IY; Ott CJ; Fasolino M; Wang Y; Kulikovskaya I; Gupta M; Yoder T; DeNizio JE; Everett JK; Williams EF; Xu J; Scholler J; Reich TJ; Bhoj VG; Haines KM; Maus MV; Melenhorst JJ; Young RM; Jadlowsky JK; Marcucci KT; Bradner JE; Levine BL; Porter DL; Bushman FD; Kohli RM; June CH; Davis MM; Lacey SF; Vahedi G; Fraietta JA
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396987
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
Le Q; Castro S; Tang T; Loeb AM; Hylkema T; McKay CN; Perkins L; Srivastava S; Call L; Smith J; Leonti A; Ries R; Pardo L; Loken MR; Correnti C; Fiorenza S; Turtle CJ; Riddell S; Tarlock K; Meshinchi S
Clin Cancer Res; 2021 Oct; 27(20):5718-5730. PubMed ID: 34380639
[TBL] [Abstract][Full Text] [Related]
16. Early-phenotype CAR-T cells for the treatment of pediatric cancers.
Meyran D; Terry RL; Zhu JJ; Haber M; Ziegler DS; Ekert PG; Trapani JA; Darcy PK; Neeson PJ
Ann Oncol; 2021 Nov; 32(11):1366-1380. PubMed ID: 34375680
[TBL] [Abstract][Full Text] [Related]
17. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
[TBL] [Abstract][Full Text] [Related]
18. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.
Leivas A; Valeri A; Córdoba L; García-Ortiz A; Ortiz A; Sánchez-Vega L; Graña-Castro O; Fernández L; Carreño-Tarragona G; Pérez M; Megías D; Paciello ML; Sánchez-Pina J; Pérez-Martínez A; Lee DA; Powell DJ; Río P; Martínez-López J
Blood Cancer J; 2021 Aug; 11(8):146. PubMed ID: 34392311
[TBL] [Abstract][Full Text] [Related]
19. Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control.
Miller IC; Zamat A; Sun LK; Phuengkham H; Harris AM; Gamboa L; Yang J; Murad JP; Priceman SJ; Kwong GA
Nat Biomed Eng; 2021 Nov; 5(11):1348-1359. PubMed ID: 34385695
[TBL] [Abstract][Full Text] [Related]
20. Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.
Chen N; Xu Y; Mou J; Rao Q; Xing H; Tian Z; Tang K; Wang M; Wang J
Blood Cancer J; 2021 Aug; 11(8):144. PubMed ID: 34392305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
